These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 17047392)

  • 1. Growth hormone receptor antagonists.
    van der Lely AJ; Kopchick JJ
    Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
    Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
    Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
    Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegvisomant and improvement of quality of life in acromegalic patients.
    Neggers SJ; van der Lely AJ
    Horm Res Paediatr; 2011; 76 Suppl 1():102-5. PubMed ID: 21778759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
    Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
    Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial.
    Madsen M; Krusenstjerna-Hafstrøm T; Møller L; Christensen B; Vendelbo MH; Pedersen SB; Frystyk J; Jessen N; Hansen TK; Stødkilde-Jørgensen H; Flyvbjerg A; Jørgensen JO
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1227-35. PubMed ID: 22298804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
    Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
    Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of pegvisomant for the treatment of acromegaly.
    Drake WM; Trainer PJ
    Treat Endocrinol; 2003; 2(6):369-74. PubMed ID: 15981941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic management of acromegaly].
    Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
    Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Yamaguchi H; Shimatsu A; Okayama A; Sato T
    Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with pegvisomant in the treatment of acromegaly.
    Drake WM
    Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New perspectives in the medical treatment of acromegaly.
    Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
    J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
    Drake WM; Parkinson C; Besser GM; Trainer PJ
    Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
    Neggers SJ; Franck SE; de Rooij FW; Dallenga AH; Poublon RM; Feelders RA; Janssen JA; Buchfelder M; Hofland LJ; Jørgensen JO; van der Lely AJ
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3644-52. PubMed ID: 24937542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.